Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al
- PMID: 30674476
- DOI: 10.1136/annrheumdis-2018-214952
Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al
Keywords: DMARDs (biologic); anti-TNF; disease activity; outcomes research.
Conflict of interest statement
Competing interests: BG: AbbVie, Biogen, Pfizer, MSD. MLH: Orion, BMS, AbbVie, Biogen, Pfizer, MSD, Celltrion. IMJH: Roche. AGL: AbbVie, MSD, Novartis, Pfizer, Roche, UCB. OH: AbbVie, Roche, Novartis. HN: AbbVie, Novartis, Medac. LSA: Pfizer.
Comment on
-
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.Ann Rheum Dis. 2019 Feb;78(2):192-200. doi: 10.1136/annrheumdis-2018-213474. Epub 2018 Nov 5. Ann Rheum Dis. 2019. PMID: 30396903
-
'To switch or not to switch': the missing piece in the puzzle of biosimilar literature?Ann Rheum Dis. 2020 Apr;79(4):e36. doi: 10.1136/annrheumdis-2018-214908. Epub 2019 Jan 4. Ann Rheum Dis. 2020. PMID: 30610068 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
